Brittenham Marissa
Chief Strategy Officer
Brittenham Marissa has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Mar 16, 2026.
On the most recent filing, Brittenham Marissa is listed as Chief Strategy Officer at Surgery Partners, Inc. Inside the rolling window, Brittenham Marissa reported no open-market purchases and 2 open-market sales totaling $166K in SGRY. The largest disclosed transaction in the window is a sale of 8,785 SGRY shares on Mar 6, 2026, worth $120K.
Companies traded
Other insiders at SGRY
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$166K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Brittenham Marissa made?
Brittenham Marissa has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.
Which companies does Brittenham Marissa trade?
Brittenham Marissa has filed SEC Form 4 disclosures for 1 company, including SGRY.
When was Brittenham Marissa's most recent SEC Form 4 filing?
Brittenham Marissa's most recent SEC Form 4 filing on Tracefour is dated Mar 16, 2026.
What is Brittenham Marissa's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Brittenham Marissa is listed as Chief Strategy Officer.
What is Brittenham Marissa's total buy and sell value in the current window?
Inside the rolling retention window, Brittenham Marissa bought $0 and sold $166K based on SEC Form 4 filings.
What was Brittenham Marissa's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 8,785 SGRY shares on 2026-03-06, worth $120K, per SEC Form 4 filings.